Cargando…

Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer

WEE1 and CHEK1 (CHK1) kinases are critical regulators of the G2/M cell cycle checkpoint and DNA damage response pathways. The WEE1 inhibitor AZD1775 and the CHK1 inhibitor SRA737 are in clinical trials for various cancers, but have not been examined in prostate cancer, particularly castration-resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qiming, Chao, Yapeng, Chen, Yuzhou, Zheng, Wenxiao, Demanelis, Kathryn, Liu, Yu, Connelly, Jaclyn, Wang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659531/ https://www.ncbi.nlm.nih.gov/pubmed/37987002 http://dx.doi.org/10.21203/rs.3.rs-3564450/v1

Ejemplares similares

Wee1 and Chk1 – crosstalk between key players in replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2019)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

The Combination of ATM and Chk1 Inhibitors Induces Synthetic Lethality in Colorectal Cancer Cells
por: Tozaki, Yuri, et al.
Publicado: (2023)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry
por: Fasulo, Barbara, et al.
Publicado: (2012)

Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells
por: Mak, Joyce P.Y., et al.
Publicado: (2015)

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
por: Zhao, Xiaoliang, et al.
Publicado: (2021)

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
por: Guertin, Amy D, et al.
Publicado: (2012)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
por: Li, Jie, et al.
Publicado: (2023)

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
por: Magnussen, Gry Irene, et al.
Publicado: (2015)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Multifaceted Functions of Protein Kinase D in Pathological Processes and Human Diseases
por: Zhang, Xuejing, et al.
Publicado: (2021)

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
por: Qi, Wenxiu, et al.
Publicado: (2014)

Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
por: Hauge, Sissel, et al.
Publicado: (2016)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma
por: Benada, Jan, et al.
Publicado: (2023)

The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer
por: Grasso, Catherine S., et al.
Publicado: (2012)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Capn3 depletion causes Chk1 and Wee1 accumulation and disrupts synchronization of cell cycle reentry during liver regeneration after partial hepatectomy
por: Chen, Feng, et al.
Publicado: (2020)

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
por: Origanti, Sofia, et al.
Publicado: (2012)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

E2F1 proteolysis via SCF‐cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition
por: Burdova, Kamila, et al.
Publicado: (2019)

miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress
por: Lezina, L, et al.
Publicado: (2013)

Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders
por: Alli, Vidya Jyothi, et al.
Publicado: (2023)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
por: Thng, Dexter Kai Hao, et al.
Publicado: (2022)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

Clinical and functional significance of CHK1-S, an alternatively spliced isoform of the CHK1 gene, in hepatocellular carcinoma
por: Hu, Guanghui, et al.
Publicado: (2020)

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
por: Yu, Xinfang, et al.
Publicado: (2020)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2c10j7rut0gmo9kfe3q3e9kgt6